First Trust NYSE Arca Biotechnology Index Fund Rating $212.95 0.00 (0.00%) Closing price 05/22/2026 04:10 PM EasternExtended Trading$212.98 +0.03 (+0.01%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsSEC FilingsShort InterestBuy This Stock First Trust NYSE Arca Biotechnology Index Fund Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FBT Aggregate RatingModerate Buy 2.67Holdings in FBT have an aggregate rating of Moderate Buy based on 470 analyst ratings issued in the past year covering 25 companies (86.3% of the portfolio).FBT Aggregate Price Target$212.95High Prediction$212.95Average Prediction$212.95Low Prediction$212.95Holdings in FBT have an aggregate price target of $212.95 and a range of $212.95 to $212.95 covering 25 companies (86.3% of the portfolio).FBT Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust NYSE Arca Biotechnology Index Fund Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 FBT Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.39%CORTCorcept Therapeutics$60.223.8452 of 5 stars2.75$70.83 17.6%8Analyst Revision4.12%AXSMAxsome Therapeutics$235.972.6009 of 5 stars2.90$251.26 6.5%213.95%VCYTVeracyte$45.031.9399 of 5 stars2.38$44.83 -0.4%8News CoverageInsider Trade3.89%NBIXNeurocrine Biosciences$156.703.8214 of 5 stars2.83$185.90 18.6%23Analyst Forecast3.86%ARWRArrowhead Pharmaceuticals$74.952.49 of 5 stars2.75$87.80 17.1%123.85%KRYSKrystal Biotech$299.453.3741 of 5 stars2.83$324.11 8.2%123.74%ILMNIllumina$144.413.2405 of 5 stars2.28$137.75 -4.6%183.71%BRKRBruker$45.692.707 of 5 stars2.47$50.54 10.6%153.64%EXELExelixis$50.152.3828 of 5 stars2.39$47.35 -5.6%233.63%ALKSAlkermes$36.802.9613 of 5 stars2.76$45.40 23.4%173.49%BIIBBiogen$193.763.8302 of 5 stars2.52$215.62 11.3%293.43%NEONeoGenomics$9.233.0836 of 5 stars2.42$13.86 50.1%123.26%VRTXVertex Pharmaceuticals$434.524.602 of 5 stars2.92$555.17 27.8%25Positive News3.24%ARGXargenex$806.464.3144 of 5 stars2.92$1,017.78 26.2%243.22%HALOHalozyme Therapeutics$68.323.9909 of 5 stars2.50$80.67 18.1%12Positive News3.22%NTRANatera$203.194.1179 of 5 stars2.79$256.60 26.3%193.21%INCYIncyte$97.164.6239 of 5 stars2.41$104.00 7.0%22Positive News3.18%UTHRUnited Therapeutics$568.433.9188 of 5 stars2.85$619.42 9.0%133.10%ONCBeOne Medicines$310.254.1556 of 5 stars2.80$389.15 25.4%153.08%BMRNBioMarin Pharmaceutical$54.094.555 of 5 stars2.75$88.67 63.9%24Analyst Forecast3.04%BNTXBioNTech$92.143.7778 of 5 stars2.68$128.44 39.4%19Analyst Downgrade3.02%AMGNAmgen$339.303.8912 of 5 stars2.48$355.19 4.7%31Positive NewsAnalyst Upgrade3.00%GILDGilead Sciences$134.364.6253 of 5 stars2.86$156.93 16.8%29Trending NewsAnalyst RevisionGap Down3.00%GMABGenmab A/S$26.873.8584 of 5 stars2.83$39.07 45.4%123.00%REGNRegeneron Pharmaceuticals$638.884.6352 of 5 stars2.70$792.65 24.1%27 This page (NYSEARCA:FBT) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust NYSE Arca Biotechnology Index Fund Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust NYSE Arca Biotechnology Index Fund With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
